The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Final CLL-FRAIL analysis supports acalabrutinib in elderly and frail patients with CLL
Florian Simon, MD, University Hospital Cologne, Cologne, Germany, discusses the final analysis of the CLL-FRAIL trial (NCT04883749) of acalabrutinib in patients with chronic lymphocytic leukemia (CLL) who are ≥80 years old or considered frail. He highlights more than three years of follow-up and reviews the durable efficacy, favorable tolerability, and sustained improvements in frailty and quality of life. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
